A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers

Oncogene

Volumn 32, Issue 11, 2013, Pages 1452-1459

  Morancho, B ^a   Parra Palau, J L ^a   Ibrahim, Y H ^a   Bernado Morales C ^a   Peg, V ^b,c   Bech Serra, J J ^a   Pandiella, A ^d   Canals, F ^a   Baselga, J ^a,e   Rubio, I ^b   Arribas, J ^a,c,f  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

^e HARVARD MEDICAL SCHOOL   (United States)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

breast cancer; ErbB2; HER2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; TRASTUZUMAB;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENES, DOMINANT; HEK293 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 84875209317     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.152     Document Type: Article

References (23)

1. Baselga J, Swain SM. Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463-475.
2. Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, Holcmann M. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2007; 75: 770-787. (Pubitemid 350086174)
3. Citri A, Yarden Y. EGF-ERBB signalling: Towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-516. (Pubitemid 44036456)
4. Abramson V, Arteaga CL. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clin Cancer Res 2011; 17: 952-958.
5. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27: 5838-5847.
6. Arribas J, Baselga J, Pedersen K, Parra-Palau JL. p95HER2 and breast cancer. Cancer Res 2011; 71: 1515-1519.
7. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007; 99: 628-638. (Pubitemid 47073544)
8. Pedersen K, Angelini PD, Laos S, Bach-Faig A, Cunningham MP, Ferrer-Ramon C et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol 2009; 29: 3319-3331.
9. Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, Diedrich G et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res 2010; 16: 4226-4235.
10. Parra-Palau JL, Pedersen K, Peg V, Scaltriti M, Angelini PD, Escorihuela M et al. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the downmodulation of the estrogen receptor in HER2-positive breast cancers. Cancer Res 2010; 70: 8537-8546.
11. Benoit V, Chariot A, Delacroix L, Deregowski V, Jacobs N, Merville MP et al. Caspase-8-dependent HER-2 cleavage in response to tumor necrosis factor alpha stimulation is counteracted by nuclear factor kappaB through c-FLIP-L expression. Cancer Res 2004; 64: 2684-2691. (Pubitemid 38500602)
12. Kulkarni S, Reddy KB, Esteva FJ, Moore HC, Budd GT, Tubbs RR. Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. Oncogene 2010; 29: 1339-1350.
13. Strohecker AM, Yehiely F, Chen F, Cryns VL. Caspase cleavage of HER-2 releases a Bad-like cell death effector. J Biol Chem 2008; 283: 18269-18282.
14. Tikhomirov O, Carpenter G. Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation. J Biol Chem 2000; 275: 26625-26631.
15. Tikhomirov O, Carpenter G. Caspase-dependent cleavage of ErbB-2 by geldanamycin and staurosporin. J Biol Chem 2001; 276: 33675-33680.
16. Tikhomirov O, Carpenter G. Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res 2003; 63: 39-43. (Pubitemid 36070417)
17. Tikhomirov O, Dikov M, Carpenter G. Identification of proteolytic fragments from ErbB-2 that induce apoptosis. Oncogene 2005; 24: 3906-3913. (Pubitemid 40896402)
18. Tompa P, Buzder-Lantos P, Tantos A, Farkas A, Szilagyi A, Banoczi Z et al. On the sequential determinants of calpain cleavage. J Biol Chem 2004; 279: 20775-20785. (Pubitemid 38656474)
19. Anelli T, Sitia R. Protein quality control in the early secretory pathway. Embo J 2008; 27: 315-327. (Pubitemid 351161662)
20. Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, Sridhara R et al. FDA drug approval summary: Lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008; 13: 1114-1119.
21. Hasui M, Saikawa Y,Miura M, Takano N, Ueno Y, Yachie A et al. Effector and precursor phenotypes of lymphokine-activated killer cells in mice with severe combined immunodeficiency (scid) and athymic (nude) mice. Cell Immunol 1989; 120: 230-239. (Pubitemid 19113726)
22. Doherty JK, Bond C, Jardim A, Adelman JP, Clinton GM. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci USA 1999; 96: 10869-10874. (Pubitemid 29442236)
23. Sanchez-Martin M, Pandiella A. Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: Therapeutic implications. Int J Cancer 2012; 131: 244-252.